We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microalbuminuria Predicts Renal Disease in Hypertension

By LabMedica International staff writers
Posted on 20 Jul 2010
The level of a protein found in urine samples, when compared to the amount of creatinine excreted, is a powerful predictor of long-term development of chronic renal insufficiency (CRI).

Increased urinary albumin is a risk factor for cardiovascular events and clinical nephropathy in patients with diabetes. More...
The urinary albumin to creatinine ratio (ACR) is used to assess the increased probability of clinical nephropathy.

In a study, conducted by Italian scientists, 917 patients who did not have diabetes but had hypertension were enrolled in the investigation and followed-up for 11.7 years. Their urine was assayed for albumin (microalbuminuria) and creatinine and the ratio calculated. Microalbuminuria occurs when the kidney leaks small amounts of albumin into the urine, in other words, when there is an abnormally high permeability for albumin in the renal glomerulus. Microalbuminuria was defined as ACR ≥ 22 mg/g in men and ACR as ≥ 31 mg/g in women.

The follow-up revealed that baseline microalbuminuria was associated with an increased risk for developing CRI; cardiovascular events, both fatal and nonfatal cardiac and cerebrovascular events; and cardiorenal events. Microalbuminuria remained significantly related to CRI and cardiorenal events even after adjustment for several baseline covariates.

The senior author on the study, Roberto Pontremoli, M.D., Ph.D., from the University of Genoa (Genoa, Italy) said. "Our findings emphasize the usefulness of a more widespread evaluation of microalbuminuria in an effort to guide the management of hypertension.” Microalbuminuria is an independent predictor of renal and cardiovascular complications in patients without diabetes and with primary hypertension.

The scientists conclude that patients with microalbuminuria should be aggressively targeted for renal and cardiovascular risk factor reduction, although further investigation is warranted to determine whether specific treatment would help to improve outcomes, as already reported for patients with diabetes. The study was reported online in April 2010 in the Clinical Journal of the American Society of Nephrology (CJASN).

Related Links:

University of Genoa




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Gastrointestinal Panel
Xpert® GI Panel
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.